A Study for Patients With Type 1 Diabetes

Exclusion Criteria

• •Twice daily use of insulin glargine within 30 days prior to the study
• •Use of any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 3 months prior to the study
• •Use of an insulin pump
• •More than 1 episode of severe hypoglycemia within 3 months prior to the study, or currently diagnosed as having hypoglycemia unawareness
• •2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months preceding the study
• •Known hypersensitivity or allergy to any of the study insulins or their excipients
• •Blood transfusion or severe blood loss within 3 months prior to the study or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology
• •Irregular sleep/wake cycle
• •Pregnant or intend to become pregnant during the study
• •Women who are breastfeeding
• •Use of prescription or over-the-counter medications to promote weight loss within 3 months prior to the study
• •Current participation in a weight loss program or plans to do so during the study
• •Use of chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy currently or within 4 weeks prior to the study
• •Cardiac disease with a marked impact on physical functioning
• •Clinically significant electrocardiogram (ECG) abnormalities at screening
• •Fasting triglycerides greater than 500 milligram per deciliter (mg/dL)
• •Liver disease
• •History of renal transplantation, current renal dialysis, or creatinine greater than 2.0 mg/dL (177 micromole per liter \[μmol/L\])
• •Malignancy other than basal cell or squamous cell skin cancer, currently or within the last 5 years
• •Treatment with any antibody-based therapy within 6 months prior to the study